These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29610053)

  • 1. Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies.
    Niimi S; Nishimiya K; Nishidate M; Saito T; Minoura K; Kadotsuji K; Shimakura J; Shigemizu H; Hosogi J; Adachi M; Hashimoto T; Mori T; Harada H; Yamamoto KI; Nakamura T; Nomura T; Yamaguchi I; Sonehara K; Ishii-Watabe A; Kawasaki N
    Drug Metab Pharmacokinet; 2018 Apr; 33(2):125-132. PubMed ID: 29610053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
    J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.
    Wu Y; Liu X; Chen Y; Woods R; Lee N; Yang H; Chowdhury P; Roskos LK; White WI
    J Pharm Biomed Anal; 2013 Dec; 86():73-81. PubMed ID: 23988731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
    Bloem K; van Leeuwen A; Verbeek G; Nurmohamed MT; Wolbink GJ; van der Kleij D; Rispens T
    J Immunol Methods; 2015 Mar; 418():29-38. PubMed ID: 25637408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody.
    Du J; Yang Y; Zhu L; Wang S; Yu C; Liu C; Long C; Chen B; Xu G; Zou L; Wang L
    Heliyon; 2023 Mar; 9(3):e13999. PubMed ID: 36915535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bridging immunogenicity assay for anti-cabiralizumab antibodies: overcoming the low assay cut point and drug tolerance challenges.
    Yuan L; Gleason CR; Stocker D; Li L; Shen JX; Ji QC
    Bioanalysis; 2021 Mar; 13(5):395-407. PubMed ID: 33661021
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of a Ligand-Binding Neutralizing Antibody Assay for Benralizumab: Comparison with an Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Cell-Based Assay.
    Wu Y; Akhgar A; Li JJ; Yu B; Chen C; Lee N; White WI; Roskos LK
    AAPS J; 2018 Mar; 20(3):49. PubMed ID: 29541868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody.
    Liao K; Meyer E; Lee TN; Loercher A; Sikkema D
    J Immunol Methods; 2017 Feb; 441():15-23. PubMed ID: 27889561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
    Xiang Y; Parng C; Olson K; Seletskaia E; Gorovits B; Jani D; Caiazzo T; Joyce A; Donley J
    AAPS J; 2019 Mar; 21(3):46. PubMed ID: 30927117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development.
    Jiang H; Xu W; Titsch CA; Furlong MT; Dodge R; Voronin K; Allentoff A; Zeng J; Aubry AF; DeSilva BS; Arnold ME
    Anal Chem; 2014 Mar; 86(5):2673-80. PubMed ID: 24506335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance.
    Kavita U; Miller W; Ji QC; Pillutla RC
    AAPS J; 2019 Jul; 21(5):92. PubMed ID: 31332587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to estimate and improve drug tolerance in anti-drug antibody assays.
    Bütikofer L; Lemaillet G; Faust H
    Bioanalysis; 2012 Aug; 4(16):1999-2012. PubMed ID: 22946916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics.
    Egging D; Verhagen J; Laat-Arts K; Wit B; Boekel TV; Buurman M; Eigenhuijsen J; Lubbers-Geuijen K; Mulder R
    Bioanalysis; 2018 Aug; 10(16):1289-1306. PubMed ID: 30130133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.
    Wang SL; Hauenstein S; Ohrmund L; Shringarpure R; Salbato J; Reddy R; McCowen K; Shah S; Lockton S; Chuang E; Singh S
    J Pharm Biomed Anal; 2013 May; 78-79():39-44. PubMed ID: 23454676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
    Pierog P; Krishna M; Yamniuk A; Chauhan A; DeSilva B
    J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.